207 related articles for article (PubMed ID: 31215336)
1. Oral treprostinil in transition or as add-on therapy in pediatric pulmonary arterial hypertension.
Ivy DD; Feinstein JA; Yung D; Mullen MP; Kirkpatrick EC; Hirsch R; Austin ED; Fineman J; Truong U; Solum D; Deng CQ; Hopper RK
Pulm Circ; 2019; 9(3):2045894019856471. PubMed ID: 31215336
[TBL] [Abstract][Full Text] [Related]
2. Transition From Subcutaneous or Inhaled Treprostinil to Oral Treprostinil at Home in Patients With Pulmonary Arterial Hypertension: A Retrospective Case Series.
Ackerbauer KA; Tandon R
J Pharm Pract; 2018 Apr; 31(2):163-166. PubMed ID: 28464760
[TBL] [Abstract][Full Text] [Related]
3. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C2 study): a randomized controlled trial.
Tapson VF; Jing ZC; Xu KF; Pan L; Feldman J; Kiely DG; Kotlyar E; McSwain CS; Laliberte K; Arneson C; Rubin LJ;
Chest; 2013 Sep; 144(3):952-958. PubMed ID: 23669822
[TBL] [Abstract][Full Text] [Related]
4. Safety and tolerability of transition from inhaled treprostinil to oral selexipag in pulmonary arterial hypertension: Results from the TRANSIT-1 study.
Frost A; Janmohamed M; Fritz JS; McConnell JW; Poch D; Fortin TA; Miller CE; Chin KM; Fisher M; Eggert M; McEvoy C; Benza RL; Farber HW; Kim NH; Pfister T; Shiraga Y; McLaughlin V
J Heart Lung Transplant; 2019 Jan; 38(1):43-50. PubMed ID: 30391194
[TBL] [Abstract][Full Text] [Related]
5. Long-term effects of inhaled treprostinil in patients with pulmonary arterial hypertension: the Treprostinil Sodium Inhalation Used in the Management of Pulmonary Arterial Hypertension (TRIUMPH) study open-label extension.
Benza RL; Seeger W; McLaughlin VV; Channick RN; Voswinckel R; Tapson VF; Robbins IM; Olschewski H; Rubin LJ
J Heart Lung Transplant; 2011 Dec; 30(12):1327-33. PubMed ID: 22055098
[TBL] [Abstract][Full Text] [Related]
6. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial.
McLaughlin VV; Benza RL; Rubin LJ; Channick RN; Voswinckel R; Tapson VF; Robbins IM; Olschewski H; Rubenfire M; Seeger W
J Am Coll Cardiol; 2010 May; 55(18):1915-22. PubMed ID: 20430262
[TBL] [Abstract][Full Text] [Related]
7. Transition from intravenous or subcutaneous prostacyclin therapy to inhaled treprostinil in patients with pulmonary arterial hypertension: a retrospective case series.
Enderby CY; Soukup M; Al Omari M; Zeiger T; Burger C
J Clin Pharm Ther; 2014 Oct; 39(5):496-500. PubMed ID: 24806480
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of transition from inhaled treprostinil to parenteral treprostinil in selected patients with pulmonary arterial hypertension.
Preston IR; Feldman J; White J; Franco V; Ishizawar D; Burger C; Waxman AB; Hill NS
Pulm Circ; 2014 Sep; 4(3):456-61. PubMed ID: 25621159
[TBL] [Abstract][Full Text] [Related]
9. Transition from parenteral to oral treprostinil in pulmonary arterial hypertension.
Chakinala MM; Feldman JP; Rischard F; Mathier M; Broderick M; Leedom N; Laliberte K; White RJ
J Heart Lung Transplant; 2017 Feb; 36(2):193-201. PubMed ID: 27469018
[TBL] [Abstract][Full Text] [Related]
10. Combination Therapy with Oral Treprostinil for Pulmonary Arterial Hypertension. A Double-Blind Placebo-controlled Clinical Trial.
White RJ; Jerjes-Sanchez C; Bohns Meyer GM; Pulido T; Sepulveda P; Wang KY; Grünig E; Hiremath S; Yu Z; Gangcheng Z; Yip WLJ; Zhang S; Khan A; Deng CQ; Grover R; Tapson VF;
Am J Respir Crit Care Med; 2020 Mar; 201(6):707-717. PubMed ID: 31765604
[No Abstract] [Full Text] [Related]
11. INSPIRE: Safety and tolerability of inhaled Yutrepia (treprostinil) in pulmonary arterial hypertension (PAH).
Hill NS; Feldman JP; Sahay S; Benza RL; Preston IR; Badesch D; Frantz RP; Patel S; Galloway A; Bull TM;
Pulm Circ; 2022 Jul; 12(3):e12119. PubMed ID: 36034402
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized, controlled trial.
Jing ZC; Parikh K; Pulido T; Jerjes-Sanchez C; White RJ; Allen R; Torbicki A; Xu KF; Yehle D; Laliberte K; Arneson C; Rubin LJ
Circulation; 2013 Feb; 127(5):624-33. PubMed ID: 23307827
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of inhaled treprostinil as add-on therapy to bosentan in pulmonary arterial hypertension.
Channick RN; Olschewski H; Seeger W; Staub T; Voswinckel R; Rubin LJ
J Am Coll Cardiol; 2006 Oct; 48(7):1433-7. PubMed ID: 17010807
[TBL] [Abstract][Full Text] [Related]
14. Transitioning from parenteral to inhaled prostacyclin therapy in pulmonary arterial hypertension.
Ataya A; Somoracki A; Cope J; Alnuaimat H
Pulm Pharmacol Ther; 2016 Oct; 40():39-43. PubMed ID: 27470680
[TBL] [Abstract][Full Text] [Related]
15. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial.
Tapson VF; Torres F; Kermeen F; Keogh AM; Allen RP; Frantz RP; Badesch DB; Frost AE; Shapiro SM; Laliberte K; Sigman J; Arneson C; Galiè N
Chest; 2012 Dec; 142(6):1383-1390. PubMed ID: 22628490
[TBL] [Abstract][Full Text] [Related]
16. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients transitioned from parenteral or inhaled prostacyclins: case series and treatment protocol.
Coons JC; Miller T; Simon MA; Ishizawar DC; Mathier MA
Pulm Circ; 2016 Mar; 6(1):132-5. PubMed ID: 27162621
[TBL] [Abstract][Full Text] [Related]
17. BREEZE: Open-label clinical study to evaluate the safety and tolerability of treprostinil inhalation powder as Tyvaso DPI™ in patients with pulmonary arterial hypertension.
Spikes LA; Bajwa AA; Burger CD; Desai SV; Eggert MS; El-Kersh KA; Fisher MR; Johri S; Joly JM; Mehta J; Palevsky HI; Ramani GV; Restrepo-Jaramillo R; Sahay S; Shah TG; Deng C; Miceli M; Smith P; Shapiro SM
Pulm Circ; 2022 Apr; 12(2):e12063. PubMed ID: 35514770
[TBL] [Abstract][Full Text] [Related]
18. One-year experience with intravenous treprostinil for pulmonary arterial hypertension.
Benza RL; Tapson VF; Gomberg-Maitland M; Poms A; Barst RJ; McLaughlin VV
J Heart Lung Transplant; 2013 Sep; 32(9):889-96. PubMed ID: 23953817
[TBL] [Abstract][Full Text] [Related]
19. Transitioning Between Prostanoid Therapies in Pulmonary Arterial Hypertension.
Pan IZ; Carey JR; Jacobs JA; Dechand J; Sessions JJ; Sorensen T; Penn BA; Mayeux JD; Hatton ND; Ryan JJ
Front Med (Lausanne); 2020; 7():81. PubMed ID: 32296704
[No Abstract] [Full Text] [Related]
20. An observational study of inhaled-treprostinil respiratory-related safety in patients with pulmonary arterial hypertension.
Zamanian RT; Levine DJ; Bourge RC; De Souza SA; Rosenzweig EB; Alnuaimat H; Burger C; Mathai SC; Leedom N; DeAngelis K; Lim A; De Marco T
Pulm Circ; 2016 Sep; 6(3):329-37. PubMed ID: 27683610
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
